Heat Biologics -- interessant! (Seite 43)

[franco51]

erholt sich wieder langsam
hab 3000st mir gekauft hoffe war keinen fehler heute

[Chrispt]

Antwort auf Beitrag Nr.: 65.641.131 von franco51 am 09.11.20 14:00:00

Ausverkauf 🙈

[franco51]

As of November 5, 2020, there were 159,845,850 shares of Common Stock, $0.0002 par value per share, outstanding.

ca 10 mio mehr aktien 🙄

[franco51]

117 mio cash nicht schlecht
aber scheint das sie die am market verkaufen

[franco51]

Heat Biologics Provides Third Quarter 2020 Business Update
Continued progress on oncology and COVID-19 vaccine programs

Over $117 million of cash and short-term investments

DURHAM, NC / ACCESSWIRE / November 9, 2020 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today provided financial, clinical and operational updates for the third quarter ended September 30, 2020.

Jeff Wolf, Chief Executive Officer of Heat, commented, "We continue to make progress on both our oncology and COVID-19 vaccine programs. We presented data for HS-110 in combination with Nivolumab in our Phase 2 lung cancer trial at the 2020 American Society of Clinical Oncology Annual Meeting demonstrating a strong survival benefit in a cohort of previously treated checkpoint inhibitor naïve patients with advanced non-small cell lung cancer (NSCLC). We are actively pursuing a variety of strategies to maximize value for the program."

"At the same time, we continue to advance PTX-35, our potential first-in-class T-cell co-stimulatory antibody, through clinical development. Earlier this year, we initiated the first clinical trial site for PTX-35 in multiple solid tumors and began dosing patients in the Phase 1 clinical trial. PTX-35 is designed to harness the body's natural antigen specific immune activation and tolerance mechanisms to reprogram immunity and provide a long-term, durable clinical effect. This study is expected to enroll up to 30 patients with advanced solid tumors refractory to standard of care."

"Importantly, we announced preclinical data for our gp96-based COVID-19 vaccine. The data, generated at the University of Miami Miller School of Medicine and published in bioRxiv, shows robust T-cell mediated immune response directed against the spike protein of SARS-CoV-2. Our gp96-based COVID-19 vaccine induced the expansion of both "killer" CD8+ T-cells that destroy virus infected cells, as well as "helper" CD4+ T-cells that assist in producing highly specific antibodies. As a result, we believe our vaccine has the potential to be used as either a standalone vaccine, or in combination with other antibody-focused vaccine approaches to enhance prophylactic protection. These results highlight the potential utility and versatility of our vaccine platform to address SARS-CoV-2, relevant mutations and other pathogens of interest."

"We continue to strengthen our IP portfolio and were recently awarded an additional U.S. patent covering Heat's gp96 platform in combination with a T cell costimulatory agonist in a single therapy. We believe the combination of our gp96 platform in a single therapy holds enormous promise in the prevention and treatment of cancer and infectious diseases, such as COVID-19."

"Finally, we have maintained a solid balance sheet with over $117 million of cash and short-term investments as of September 30, 2020. We believe this capital will provide us significant runway to achieve a number of important clinical milestones that we believe will drive value for shareholders in the months and years ahead," concluded Mr. Wolf.

Third Quarter 2020 Financial Results

Recognized $0.8 million of grant revenue for qualified expenditures under the CPRIT and NIH grant. No grant revenue was recognized under the respective grants for the three months ended September 30, 2019. The increase in grant revenue in the current-year period primarily reflects the expected timing of completion of deliveries under the current phase of the contracts. As of September 30, 2020, we had deferred revenue of $1.2 million for CPRIT proceeds received but for which the costs had not been incurred or the conditions of the award had not been met.
Research and development expenses was $3.2 million and $3.1 million for the three months ended September 30, 2020 and 2019, respectively.
General and administrative expense was $6.6 million and $2.0 million for the three months ended September 30, 2020 and 2019. General and administrative expenses primarily consist of personnel costs, including stock-based compensation expense, and consulting expenses to manage the business.
Net loss attributable to Heat Biologics was approximately $8.9 million, or ($0.06) per basic and diluted share for the quarter ended September 30, 2020 compared to a net loss of approximately of $6.2 million, or ($0.18) per basic and diluted share for the quarter ended September 30, 2019.
As of September 30, 2020, the Company had approximately $117.3 million in cash, cash equivalents and short investments.
About Heat Biologics, Inc.

[Hitman2]

https://newsfilter.io/a/b9d744a32979acbf76943594b81c5717

[rsch]

Antwort auf Beitrag Nr.: 65.622.620 von Ich-nix-Schuld am 06.11.20 19:42:33

Schön unser Federvieh blickt wieder durch, ich keine ahnung

[Ich-nix-Schuld]

Interessiert wohl keinen mehr. Die Börse hat sich an Corona gewöhnt. Der Virus ist ja auch nicht mehr so gefährlich. Ich warte bis Januar. Dann ist der Cannabis Rausch von den Ammis hoffentlich Geschichte😂

[Eulenfoerster]

[T-Zellen reagieren verspätet: Coronavirus-Patienten offenbar nach 6 Monaten noch immun] https://va.newsrepublic.net/al/pfkjppR

[Hitman2]

Asien https://www.youtube.com/watch?v=xhJhLX379X8